Final CMS decision limits coverage of Biogen’s Aduhelm to those in clinical trials

 
Medicare will only cover Biogen Alzheimer’s disease drug Aduhelm for beneficiaries enrolled in a clinical trial, a decision that limits use of that product and also affects experimental medications still in development for the neurodegenerative disorder. That’s because this coverage…

Source: medcitynews.com – Read more